Blood Clots Clinical Trials

Find Blood Clots Clinical Trials Near You

Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The goal of this observational study is to learn how the immune system responds to myeloproliferative neoplasms (MPN) in adults with known or suspected MPN. Researchers also want to identify immune cells that could help develop future immune-based treatments for MPN. The main questions it aims to answer are: * Are there T cells in the bone marrow that can recognize MPN cells? * Which targets (antigens) on MPN cells are recognized by these immune cells? * Can researchers identify T cell receptors (TCRs) that may be used in future TCR-based therapies? Researchers will study samples from adults with polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), post-PMF, or unclassifiable MPN. Samples from healthy donors without blood disorders will also be included for comparison. By providing blood and bone marrow samples, participants will: * Allow researchers to study immune cells and genetic material from these samples * Allow researchers to perform laboratory tests to study how immune cells recognize MPN cells Researchers will use laboratory methods such as genetic sequencing, cell analysis, and cell culture experiments to better understand immune responses in MPN. Participants will not receive direct medical benefit from this study. The results may help researchers better understand MPN and support the future development of immune-based therapies.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Patients previously diagnosed or suspected of having PV, ET, pre-PMF, overt PMF, or an unclassifiable MPN.

• Patients not previously diagnosed with a haematological disease as controls

Locations
Other Locations
Belgium
de Duve Institute, UCLouvain
RECRUITING
Brussels
Contact Information
Primary
Sophie Lucas
sophie.lucas@uclouvain.be
0032 (0)2 436 23 00
Time Frame
Start Date: 2026-05
Estimated Completion Date: 2037-01
Participants
Target number of participants: 150
Sponsors
Leads: Université Catholique de Louvain

This content was sourced from clinicaltrials.gov

Similar Clinical Trials